30 June 2026

# First case completed in jaw reconstruction trial at the Princess Alexandra Hospital

## Highlights

- **Osteopore is delighted to announce that the first patient for the jaw reconstruction clinical trial, conducted at the Princess Alexandra Hospital (PAH), has been successfully treated with Osteopore's novel implant.**
- **As previously announced on 4 June 2025[1] and 21 July 2025[2], Osteopore and Princess Alexandra Hospital (PAH) were given approval to commence a jawbone reconstruction clinical trial with Osteopore's novel implant.**
- **The single-arm feasibility study aims to recruit at least 10 adult patients in Australia by 2028. Each patient will be assessed 36 months post-surgery.**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that the first patient for the jaw reconstruction clinical trial, conducted at the Princess Alexandra Hospital (PAH), has been successfully treated with Osteopore's novel implant.

As previously announced on 4 June 2025[1] and 21 July 2025[2], Osteopore and Princess Alexandra Hospital (PAH) were given approval to commence a jawbone reconstruction clinical trial with Osteopore's novel implant.

[1] ASX announcement, "Osteopore launches clinical study for jawbone reconstruction", 4 June 2025.

[2] ASX announcement, "Jaw recon trial approved, first patient to be recruited", 21 July 2025.

The trial, led by Dr. Michael Wagels, a Plastic and Reconstructive Surgeon based at PAH, is a single-arm feasibility study that aims to recruit at least 10 adult patients in Australia by 2028. Each patient will be assessed 36 months post-surgery.

The loss of bone in the maxilla or mandible can significantly impact function and appearance, affecting basic abilities such as breathing, chewing, swallowing and speaking. These bones also play a key role in facial aesthetics, which is closely linked to psychosocial well-being.

Currently, autologous free tissue transfer is considered a state-of-the-art treatment. However, it comes with intrinsic donor site morbidity, limited adaptability for complex defects, a shortage of available donor site bone, and insufficient bone height for effective dental rehabilitation.

This novel implant addresses these limitations directly as it is made specific to the patient's anatomy using 3D printing, while allowing the incorporation of bone inducing factors to regenerate high quality bone for the patient.

**ENDS**

*This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

**Mark Leong**
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

**Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.